NeoGenomics, Inc. launched PTEN IHC CDx, the first FDA-approved immunohistochemistry companion diagnostic for prostate adenocarcinoma. The test identifies PTEN protein loss to determine patient eligibility for AstraZeneca’s recently approved targeted therapy, TRUQAP (capivasertib).
The diagnostic tool expands NeoGenomics' service portfolio into urologic oncology. Clinicians can order the test individually or as part of the NEO PanTracer Pro comprehensive molecular analysis.
This launch positions NeoGenomics as a primary provider for community oncology practices managing advanced prostate cancer. The tool streamlines the identification of patients eligible for new therapeutic options.